Ovid Therapeutics Inc. OVID
Set alert
At close · Nov 2
After hours · Nov 2, 4:35 PM ET
- YTD
- +46.63%
- 1 year
- +71.94%
- Open
- 2.55
- Prev close
- 2.54
- Mkt cap
- 466.76M
- Vol
- 2.34M
- Avg vol
- 1.70M
- EPS
- -0.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.37
- High
- 2.60
- Forward P/E
- -2.44
- Beta
- 0.41
- Short ratio
- 3.05
- Inst. own
- 56.41%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.14
- 200-d avg
- 1.76
- 1y target
- 3.26
5D chart
Signals (72)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 1:15 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 12:15 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 12:15 PM | 10 hours ago |
| MACD: Buy Signal | Nov 2, 11:30 AM | 11 hours ago |
| SMA: Bullish | Nov 2, 11:25 AM | 11 hours ago |
| RSI: Oversold | Nov 2, 11:15 AM | 11 hours ago |
| SMA: Bearish | Nov 2, 11:05 AM | 11 hours ago |
| SMA: Bullish | Nov 2, 11:00 AM | 11 hours ago |
| RSI: Oversold | Nov 2, 10:15 AM | 12 hours ago |
| MACD: Sell Signal | Nov 2, 10:00 AM | 12 hours ago |
| SMA: Bearish | Nov 2, 9:45 AM | 12 hours ago |
| SMA: Bearish | Nov 2, 9:45 AM | 12 hours ago |
| SMA: Bullish | Nov 2, 9:35 AM | 13 hours ago |
| MACD: Buy Signal | Nov 2, 9:30 AM | 13 hours ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| RSI: Overbought | Oct 30, 11:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:00 PM | 4 days ago |
| RSI: Overbought | Oct 29, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 5 days ago |
| RSI: Overbought | Oct 28, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:25 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:15 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| RSI: Overbought | Oct 27, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 6 days ago |
News
-
2 weeks ago benzinga.com
Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5
Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
-
3 weeks ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.
-
3 weeks ago benzinga.com
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
-
4 weeks ago benzinga.com
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
1 month ago benzinga.com
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.
2 months ago globenewswire.com
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
2 months ago defenseworld.net
BlackRock Inc. Takes Position in Ovid Therapeutics $OVID
BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange…
2 months ago zacks.com
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 months ago zacks.com
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
-
2 months ago benzinga.com
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of…
2 months ago globenewswire.com
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
2 months ago zacks.com
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
3 months ago benzinga.com
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
3 months ago defenseworld.net
Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID
Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
3 months ago defenseworld.net
ADAR1 Capital Management LLC Acquires 259,113 Shares of Ovid Therapeutics $OVID
ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
-
3 months ago benzinga.com
Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona
Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer,…
3 months ago globenewswire.com
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
3 months ago seekingalpha.com
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated…
3 months ago seekingalpha.com
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions
Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and…
3 months ago benzinga.com
Rivian, Micron And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announcement. Other stocks also down in pre-market.
4 months ago benzinga.com
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related serious adverse events.
5 months ago globenewswire.com
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
5 months ago globenewswire.com
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
-
5 months ago benzinga.com
Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of…
5 months ago globenewswire.com
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable…
6 months ago proactiveinvestors.com
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic…
6 months ago seekingalpha.com
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
6 months ago globenewswire.com
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,…
7 months ago defenseworld.net
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports.…
7 months ago seekingalpha.com
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 months ago benzinga.com
Earnings Scheduled For March 18, 2026
Earnings Scheduled For March 18, 2026
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
11 months ago benzinga.com
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
2 years ago benzinga.com
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
3 years ago benzinga.com
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
-
3 years ago benzinga.com
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 184 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.